Simplified production of a recombinant human angiostatin derivative that suppresses intracerebral glial tumor growth

Patricio I. Meneses, Lauren E. Abrey, Katherine A. Hajjar, Sakir Gultekin, Robert Duvoisin, Kenneth I. Berns, Myrna R. Rosenfeld

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Angiostatin is an endogenous inhibitor of tumor neovascularization that inhibits the proliferation of endothelial cells. Production of sufficient quantities of biologically active angiostatin by the enzymatic cleavage of plasminogen has proven difficult in that it has delayed clinical testing. We have cloned, expressed, and purified a recombinant human angiostatin derivative (K1-3) using a mammalian expression system. Through the addition of a secretory signal and polyhistidine sequence tag, K1-3 can be purified from postculture medium by simple column chromatography. Purified K1-3 protein is apparently folded in an active conformation, as evidenced by its ability to bind to lysine-Sepharose. In vitro, recombinant K1-3 significantly suppressed endothelial cell proliferation in a dose-dependent manner with an IC50 of 50 nM. Using an animal model of intracranial brain tumors in immune-competent rats, systemic administration of purified recombinant K1-3 resulted in up to 85% suppression of tumor growth (P = 0.011). Growth suppression was accompanied by a 32% decrease (P = 0.01) in tumor neovascularization. This study demonstrates a simple method to produce a biologically active recombinant angiostatin derivative. The ability to suppress intracerebral tumor growth after systemic administration suggests that K1-3 is likely to have therapeutic value in the treatment of malignant glial tumors.

Original languageEnglish (US)
Pages (from-to)3689-3694
Number of pages6
JournalClinical Cancer Research
Volume5
Issue number11
StatePublished - Nov 1999
Externally publishedYes

Fingerprint

Angiostatins
Neuroglia
Growth
Neoplasms
Endothelial Cells
Angiogenesis Inhibitors
Plasminogen
Protein Sorting Signals
Brain Neoplasms
Inhibitory Concentration 50
Chromatography
Animal Models
Cell Proliferation
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Meneses, P. I., Abrey, L. E., Hajjar, K. A., Gultekin, S., Duvoisin, R., Berns, K. I., & Rosenfeld, M. R. (1999). Simplified production of a recombinant human angiostatin derivative that suppresses intracerebral glial tumor growth. Clinical Cancer Research, 5(11), 3689-3694.

Simplified production of a recombinant human angiostatin derivative that suppresses intracerebral glial tumor growth. / Meneses, Patricio I.; Abrey, Lauren E.; Hajjar, Katherine A.; Gultekin, Sakir; Duvoisin, Robert; Berns, Kenneth I.; Rosenfeld, Myrna R.

In: Clinical Cancer Research, Vol. 5, No. 11, 11.1999, p. 3689-3694.

Research output: Contribution to journalArticle

Meneses, PI, Abrey, LE, Hajjar, KA, Gultekin, S, Duvoisin, R, Berns, KI & Rosenfeld, MR 1999, 'Simplified production of a recombinant human angiostatin derivative that suppresses intracerebral glial tumor growth', Clinical Cancer Research, vol. 5, no. 11, pp. 3689-3694.
Meneses, Patricio I. ; Abrey, Lauren E. ; Hajjar, Katherine A. ; Gultekin, Sakir ; Duvoisin, Robert ; Berns, Kenneth I. ; Rosenfeld, Myrna R. / Simplified production of a recombinant human angiostatin derivative that suppresses intracerebral glial tumor growth. In: Clinical Cancer Research. 1999 ; Vol. 5, No. 11. pp. 3689-3694.
@article{ad5bc3193b3a494cb9d6265c23392c64,
title = "Simplified production of a recombinant human angiostatin derivative that suppresses intracerebral glial tumor growth",
abstract = "Angiostatin is an endogenous inhibitor of tumor neovascularization that inhibits the proliferation of endothelial cells. Production of sufficient quantities of biologically active angiostatin by the enzymatic cleavage of plasminogen has proven difficult in that it has delayed clinical testing. We have cloned, expressed, and purified a recombinant human angiostatin derivative (K1-3) using a mammalian expression system. Through the addition of a secretory signal and polyhistidine sequence tag, K1-3 can be purified from postculture medium by simple column chromatography. Purified K1-3 protein is apparently folded in an active conformation, as evidenced by its ability to bind to lysine-Sepharose. In vitro, recombinant K1-3 significantly suppressed endothelial cell proliferation in a dose-dependent manner with an IC50 of 50 nM. Using an animal model of intracranial brain tumors in immune-competent rats, systemic administration of purified recombinant K1-3 resulted in up to 85{\%} suppression of tumor growth (P = 0.011). Growth suppression was accompanied by a 32{\%} decrease (P = 0.01) in tumor neovascularization. This study demonstrates a simple method to produce a biologically active recombinant angiostatin derivative. The ability to suppress intracerebral tumor growth after systemic administration suggests that K1-3 is likely to have therapeutic value in the treatment of malignant glial tumors.",
author = "Meneses, {Patricio I.} and Abrey, {Lauren E.} and Hajjar, {Katherine A.} and Sakir Gultekin and Robert Duvoisin and Berns, {Kenneth I.} and Rosenfeld, {Myrna R.}",
year = "1999",
month = "11",
language = "English (US)",
volume = "5",
pages = "3689--3694",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Simplified production of a recombinant human angiostatin derivative that suppresses intracerebral glial tumor growth

AU - Meneses, Patricio I.

AU - Abrey, Lauren E.

AU - Hajjar, Katherine A.

AU - Gultekin, Sakir

AU - Duvoisin, Robert

AU - Berns, Kenneth I.

AU - Rosenfeld, Myrna R.

PY - 1999/11

Y1 - 1999/11

N2 - Angiostatin is an endogenous inhibitor of tumor neovascularization that inhibits the proliferation of endothelial cells. Production of sufficient quantities of biologically active angiostatin by the enzymatic cleavage of plasminogen has proven difficult in that it has delayed clinical testing. We have cloned, expressed, and purified a recombinant human angiostatin derivative (K1-3) using a mammalian expression system. Through the addition of a secretory signal and polyhistidine sequence tag, K1-3 can be purified from postculture medium by simple column chromatography. Purified K1-3 protein is apparently folded in an active conformation, as evidenced by its ability to bind to lysine-Sepharose. In vitro, recombinant K1-3 significantly suppressed endothelial cell proliferation in a dose-dependent manner with an IC50 of 50 nM. Using an animal model of intracranial brain tumors in immune-competent rats, systemic administration of purified recombinant K1-3 resulted in up to 85% suppression of tumor growth (P = 0.011). Growth suppression was accompanied by a 32% decrease (P = 0.01) in tumor neovascularization. This study demonstrates a simple method to produce a biologically active recombinant angiostatin derivative. The ability to suppress intracerebral tumor growth after systemic administration suggests that K1-3 is likely to have therapeutic value in the treatment of malignant glial tumors.

AB - Angiostatin is an endogenous inhibitor of tumor neovascularization that inhibits the proliferation of endothelial cells. Production of sufficient quantities of biologically active angiostatin by the enzymatic cleavage of plasminogen has proven difficult in that it has delayed clinical testing. We have cloned, expressed, and purified a recombinant human angiostatin derivative (K1-3) using a mammalian expression system. Through the addition of a secretory signal and polyhistidine sequence tag, K1-3 can be purified from postculture medium by simple column chromatography. Purified K1-3 protein is apparently folded in an active conformation, as evidenced by its ability to bind to lysine-Sepharose. In vitro, recombinant K1-3 significantly suppressed endothelial cell proliferation in a dose-dependent manner with an IC50 of 50 nM. Using an animal model of intracranial brain tumors in immune-competent rats, systemic administration of purified recombinant K1-3 resulted in up to 85% suppression of tumor growth (P = 0.011). Growth suppression was accompanied by a 32% decrease (P = 0.01) in tumor neovascularization. This study demonstrates a simple method to produce a biologically active recombinant angiostatin derivative. The ability to suppress intracerebral tumor growth after systemic administration suggests that K1-3 is likely to have therapeutic value in the treatment of malignant glial tumors.

UR - http://www.scopus.com/inward/record.url?scp=0032713943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032713943&partnerID=8YFLogxK

M3 - Article

C2 - 10589788

AN - SCOPUS:0032713943

VL - 5

SP - 3689

EP - 3694

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -